Evaluation of Doxycycline Post-exposure Prophylaxis to Reduce Sexually Transmitted Infections in PrEP Users and HIV-infected Men Who Have Sex With Men
Conditions: Gonorrhea; Chlamydia; Syphilis Intervention: Drug: Doxycycline Hyclate Delayed-Release 200 mg Sponsors: University of California, San Francisco; University of Washington; National Institute of Allergy and Infectious Diseases (NIAID); Mayne Pharma International Pty Ltd; San Francisco Department of Public Health Not yet recruiting
(NIH/National Institute of Allergy and Infectious Diseases) The National Institute of Allergy and Infectious Diseases (NIAID) today announced awards to establish four Cooperative Research Centers (CRCs) focused on developing vaccines to prevent sexually transmitted infections (STIs). The grants, totaling $41.6 million over five years, will support collaborative, multidisciplinary research on the bacteria that cause syphilis, gonorrhea and chlamydia. At the end of the program, each center is expected to identify at least one candidate vaccine ready for testing in clinical trials.
Publication date: Available online 8 February 2017 Source:The Lancet HIV Author(s): Beatriz Grinsztejn, Emilia M Jalil, Laylla Monteiro, Luciane Velasque, Ronaldo I Moreira, Ana Cristina F Garcia, Cristiane V Castro, Alícia Krüger, Paula M Luz, Albert Y Liu, Willi McFarland, Susan Buchbinder, Valdilea G Veloso, Erin C Wilson Background The burden of HIV in transgender women (transwomen) in Brazil remains unknown. We aimed to estimate HIV prevalence among transwomen in Rio de Janeiro and to identify predictors of newly diagnosed HIV infections. Methods We recruited transwomen from Rio de Janeiro, Brazil, by res...